Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00711009

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) — PROGRESS  

Human Immunodeficiency Virus Infection Clinical Trial

Official title:
A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects

Clinical Trial Summary

The purpose of this study is to compare the safety, tolerability, and antiviral activity of the lopinavir/ritonavir tablet when administered in combination with reverse transcriptase inhibitors to lopinavir/ritonavir tablets when administered in combination with a human immunodeficiency virus type 1 ( HIV-1) integrase inhibitor in antiretroviral naive HIV-1 infected subjects.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00711009
Study type Interventional
Source Abbott
Contact
Status Completed
Phase Phase 3
Start date July 2008
Completion date October 2010
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05981807 - HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Completed NCT01490359 - Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men N/A
Completed NCT03143205 - Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men N/A
Completed NCT02738138 - A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) Phase 3
Completed NCT01791465 - Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults Phase 4
Completed NCT01869634 - Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Phase 4
Completed NCT01662336 - Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program N/A
Completed NCT01383005 - Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) N/A
Completed NCT01328158 - Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection N/A
Completed NCT02817451 - DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Phase 3
Completed NCT02214173 - The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV N/A
Completed NCT03284645 - Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
Terminated NCT01737359 - A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. Phase 2
Active, not recruiting NCT05141422 - A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers Phase 1
Completed NCT01939197 - A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Phase 2/Phase 3
Completed NCT01447680 - Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing N/A
Not yet recruiting NCT05769413 - Awareness of Osteoporosis in HIV Patients
Withdrawn NCT01738555 - A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects Phase 2